Saturn V Capital Management LP — 13F Holdings & Portfolio
CIK 1964437 · latest 13F-HR filed 2026-08-14
Saturn V Capital Management LP manages $697.5M in 13F-reported U.S. long-equity assets across 23 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are AMLX (11.91%), ALMS (11.76%), ABVX (9.91%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 3 new positions and exited 1; 16 existing positions rose in reported value and 3 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 75.6%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Aug 4, 2026.
SUITE 1030
AUSTIN, TX 78701
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| EDWARDS, DOUGLAS, KEVIN Control | CHIEF COMPLIANCE OFFICER since May 2023 | Less than 5% | Individual |
| TIAN, XIAOYING, (NMN) Control | LIMITED PARTNER since Sep 2023 | 75% or more | Individual |
| SVCM GP LLC | GENERAL PARTNER since Sep 2023 | Less than 5% | Domestic Entity |
| TIAN, XIAOYING, (NMN) Control Indirect owner via SVCM GP LLC | MANAGING MEMBER since Sep 2023 | 75% or more | Individual |
Ownership & leadership changes · 2 filings with changes since Feb 23, 2022
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- AddedSVCM GP LLC · GENERAL PARTNER · Less than 5%
- AddedTIAN, XIAOYING, (NMN) · MANAGING MEMBER · 75% or more · indirect via SVCM GP LLC · control person
- ChangedTIAN, XIAOYING, (NMN) · title MANAGING MEMBER → LIMITED PARTNER
- No longer listedSATURN V CAPITAL GP LLC · GENERAL PARTNER · Less than 5% · control person · listed since Mar 2021
- AddedEDWARDS, DOUGLAS, KEVIN · CHIEF COMPLIANCE OFFICER · Less than 5% · control person
- ListedSATURN V CAPITAL GP LLC · GENERAL PARTNER · Less than 5% · control person
- ListedTIAN, XIAOYING, (NMN) · MANAGING MEMBER · 75% or more · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- AMYLYX PHARMACEUTICALS INC$22.6M +37.4%
- CANDEL THERAPEUTICS INC$19.8M +139.7%
- IMMIX BIOPHARMA INC$14.4M +42.7%
- PHARVARIS N V$11.5M +33.9%
- ALUMIS INC$11.5M +16.3%
Top Trims
- OVID THERAPEUTICS INC-$7.5M -80.7%
- INVIVYD INC-$6.9M -48.6%
- OCULIS HOLDING AG-$4.2M -30.9%
New Positions
- TREVI THERAPEUTICS INC$19.6M
- SAGIMET BIOSCIENCES INC$11.4M
- VIR BIOTECHNOLOGY INC$7.9M
Saturn V Capital Management LP Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | AMYLYX PHARMACEUTICALS INC | AMLX | 03237H101 | $83.0M | 11.91% | 4,624,101 | SH |
| 2 | ALUMIS INC | ALMS | 022307102 | $82.0M | 11.76% | 2,915,443 | SH |
| 3 | ABIVAX SA | ABVX | 00370M103 | $69.1M | 9.91% | 518,865 | SH |
| 4 | VAXCYTE INC | PCVX | 92243G108 | $49.6M | 7.11% | 852,914 | SH |
| 5 | IMMIX BIOPHARMA INC | IMMX | 45258H106 | $48.0M | 6.89% | 4,658,429 | SH |
| 6 | PHARVARIS N V | PHVS | N69605108 | $45.4M | 6.52% | 1,314,122 | SH |
| 7 | JAZZ PHARMACEUTICALS PLC | JAZZ | G50871105 | $38.8M | 5.56% | 160,938 | SH |
| 8 | CELCUITY INC | CELC | 15102K100 | $38.7M | 5.55% | 370,318 | SH |
| 9 | DISC MEDICINE INC | IRON | 254604101 | $38.4M | 5.50% | 524,730 | SH |
| 10 | CANDEL THERAPEUTICS INC | CADL | 137404109 | $34.0M | 4.88% | 3,303,686 | SH |
| 11 | X4 PHARMACEUTICALS INC | XFOR | 98420X202 | $32.6M | 4.67% | 6,973,343 | SH |
| 12 | MONOPAR THERAPEUTICS INC | MNPR | 61023L207 | $28.9M | 4.14% | 311,976 | SH |
| 13 | DYNE THERAPEUTICS INC | DYN | 26818M108 | $23.5M | 3.37% | 1,057,493 | SH |
| 14 | TREVI THERAPEUTICS INC | TRVI | 89532M101 | $19.6M | 2.81% | 1,052,043 | SH |
| 15 | ZURA BIO LTD | ZURA | G9TY5A101 | $12.4M | 1.78% | 2,101,119 | SH |
| 16 | SAGIMET BIOSCIENCES INC | SGMT | 786700104 | $11.4M | 1.64% | 1,479,918 | SH |
| 17 | OCULIS HOLDING AG | OCS | H5870P102 | $9.5M | 1.36% | 684,880 | SH |
| 18 | INHIBIKASE THERAPEUTICS INC | IKT | 45719W205 | $7.9M | 1.13% | 3,869,056 | SH |
| 19 | VIR BIOTECHNOLOGY INC | VIR | 92764N102 | $7.9M | 1.13% | 770,643 | SH |
| 20 | INVIVYD INC | IVVD | 00534A102 | $7.3M | 1.05% | 8,392,288 | SH |
| 21 | ALTO NEUROSCIENCE INC | ANRO | 02157Q109 | $4.8M | 0.69% | 182,829 | SH |
| 22 | SATELLOS BIOSCIENCE INC | MSLE | 80401L803 | $2.7M | 0.39% | 350,000 | SH |
| 23 | OVID THERAPEUTICS INC | OVID | 690469101 | $1.8M | 0.26% | 663,060 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $697.5M | 23 | 0001964437-26-000012 |
| 2026-03-31 | 2026-05-15 | $552.2M | 21 | 0001964437-26-000005 |
| 2025-12-31 | 2026-02-17 | $544.9M | 20 | 0001964437-26-000003 |
| 2025-09-30 | 2025-11-14 | $456.0M | 17 | 0001964437-25-000013 |
SUITE 1030
AUSTIN, TX 78701-2102